The U.S. Food and Drug Administration placed a partial clinical hold on studies conducted by Gilead Sciences assessing the combination of magrolimab plus azacitidine due to concerns of unexpected serious adverse events between study arms.
If you are not happy with the results below please do another search
50 search results for:
An appeals court judge on Jan. 25 granted a stay in an appeal over mask mandates in New York, keeping the rule in effect during the legal process, New York Attorney General Letitia James said.
BioNTech said the company and partner Pfizer may not be able to stick with their plan to launch an Omicron-targeting vaccine by the end of March 2022, depending on how much clinical trial data regulators will require.
The Omicron variant appears to result in less severe COVID-19 than seen during previous periods of high coronavirus transmission including the Delta wave, with shorter hospital stays, less need for intensive care and fewer deaths, according to a new U.S. study.
U.S. financial contributions to the World Health Organization (WHO) have fallen by 25 percent during the coronavirus pandemic, provisional data show, with Washington’s future support to the United Nations agency under review.
The MIT Center for Collective Intelligence and MilliporeSigma brought together the thought-power of gurus in science, healthcare, public policy and other sectors to answer the question: how do we apply what we have learned from the COVID-19 pandemic for the future?
When AstraZeneca presented positive updated results from the Phase III ASCEND study of CALQUENCE (acalabrutinib), it marked an important milestone for the company as the jewel in the crown of what management hopes will become a significant hematology portfolio. That study was significant for patients, too, because it represented a landmark 36 months of follow-up in chronic lymphocytic leukemia (CLL), which is considered an incurable disease.
Pfizer Inc. and BioNTech SE said on Jan. 25 they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.
Rhode Island on Jan. 25 reversed course and threw the state’s support behind a $21 billion nationwide settlement it originally declined to back resolving lawsuits alleging that three large drug distributors fueled the deadly U.S. opioid epidemic.
Early research suggesting that a popular non-psychoactive compound derived from marijuana might help prevent or treat COVID-19 warrants further investigation in rigorous clinical trials, researchers say.